It was evaluated in a randomized phase 2 trial involving older individuals who had experienced a fall due to reduced muscle strength.[69] In contrast to MYO-029, which was found to be safe but insufficiently effective in producing a robust increase in muscle mass,[70] landogrozumab effectively increased lean body mass and improved overall physical performance in a geriatric population with diminished muscle strength.[69] However, due to the high similarity between MSTN and GDF11, many anti-MSTN antibodies have been reported to also bind to GDF11, raising concerns about potential side effects resulting from GDF11 inhibition
If you have a history of prior clots or active cancer, consider contacting your specialist before starting or continuing therapy
In gut endocrine cells, proglucagon is processed to glicentin, oxyntomodulin, GLP-1 and GLP-2, all of which have biological activity (28)
3eg and Supplementary Fig
The influence of GLP-1 receptor agonists on heart failure with reduced ejection fraction has been investigated so far only by two small clinical trials, the FIGHT and the LIVE trial